Transactions

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement For New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-VNCG)

NEW YORK, NY, and SAINT PREX, SWITZERLAND, August 24, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

Transactions

NEW YORK, NY, and BOSTON, MA, March 23, 2023 - Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry, and PureTech Health plc

Royalty Pharma and Ionis Enter into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

Transactions

NEW YORK, NY, and CARLSBAD, CA, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Royalty Pharma has acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA®

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran from Arrowhead for $250 Million and Future Milestones

Transactions

NEW YORK, NY, and PASADENA, CA, November 9, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in cash

Royalty Pharma Announces R&D Funding Collaboration with Merck

Transactions

NEW YORK, NY, October 12, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an

Royalty Pharma Agrees to Acquire Royalty Interest in Trelegy Ellipta From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Transactions

NEW YORK, July 13, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in Trelegy Ellipta (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

Transactions

NEW YORK, NY, June 30, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million

Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million

Transactions

NEW YORK, NY and SOUTH SAN FRANCISCO, CA, January 7, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and Orladeyo from Biocryst Pharmaceuticals

Transactions

NEW YORK, NY and RESEARCH TRIANGLE PARK, NC, November 22, 2021 – Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership with MorphoSys

Transactions

NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals

Transactions

Stay up to date